Partnerships present a unique opportunity to expand services and drive greater value. The concept of working separately but together is advantageous in the way that
Pharmacy plan designs encompass everything from cost-sharing arrangements to formulary management to utilization review programs. When combined, they create a well-managed pharmacy plan that drives
After several years of debate and various proposals, Congress has passed prescription drug reform. Although the full impact of the bill is not yet understood,
One area of health care rapidly gaining popularity is digital therapeutics (DTx). These are advanced medical devices that deliver software-based interventions to patients to treat,
For most people, the beginning of March means spring cleaning — but have you ever thought of spring cleaning your medicine cabinet? It is important
Patient assistance dollars from pharmaceutical companies have been a growing area in recent years. Assistance dollars have risen exponentially as pharmaceutical companies work to get
There seems to be enthusiasm as we all turn our backs on 2021. Enthusiasm for 2022 is coming with a much more cautious tone. In
In 2020, the world experienced an incredibly fast vaccine approval, with the Pfizer COVID-19 vaccine receiving emergency use authorization from the U.S. Food and Drug
Diabetes Management Diabetes is a complex and progressive medical condition associated with abnormally elevated blood sugar levels. If left untreated or uncontrolled, diabetes may cause
Lowering Costs and Improving Participant Experience In the constantly evolving pharmacy benefit management (PBM) industry, pharmacy expenses and participants’ expectations continue to rise. To keep
In case you missed it, National CooperativeRx produced a webinar educating the audience on biologic drugs and regulatory implications, the current market status of biosimilars and
The Cooperative’s new Advanced Criteria Updates Program has officially launched! National CooperativeRx constantly monitors the pharmaceutical marketplace for new therapies in the pipeline. We have